Rimegepant

Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven Pharmaceuticals. Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven Pharmaceuticals. Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.